Feb 21, 2006 | NEWS
February 21, 2006 deCODE genetics (Nasdaq:DCGN) today announced top-line results from Phase I clinical studies of DG041, the company’s developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of...
Jan 18, 2006 | NEWS
January 18, 2006 deCODE genetics (Nasdaq:DCGN) today announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company’s unique...
Jan 15, 2006 | NEWS
January 15, 2006 In a scientific paper published today a team of scientists from deCODE genetics (Nasdaq:DCGN) and colleagues report the discovery of a variant in a gene on chromosome 10 that represents the most significant genetic risk factor for type 2 diabetes...
Nov 10, 2005 | NEWS
November 10, 2005 Major discovery with rapid applicability to the development of new medicine Reykjavik, ICELAND, November 10, 2005 – A paper by a deCODE-led team of scientists published today presents the discovery of a gene variant conferring increased risk of...
May 18, 2005 | NEWS
Reykjavik, ICELAND, May 18, 2005 – deCODE genetics (Nasdaq:DCGN) today announced that it has begun dosing of patients in a Phase II clinical trial in asthma. deCODE has isolated a gene which plays an important role in the development of asthma. The gene encodes a...
May 10, 2005 | NEWS
Reykjavik, ICELAND, May 10, 2005 – deCODE genetics (Nasdaq:DCGN) today announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company’s lead compound being developed for the...
